Page 1

inflaRx • • • • InflaRx Reports Second Quarter 2021 Financial & Operating Results Severe COVID - 19 trial enrollment reaches 299 patients ; an independent data monitoring committee has recommended to continue the trial as planned after analyzing data from the first 180 evaluable patients Type A meeting request submitted to further discuss primary endpoint for the Phase III clinical development of vilobelimab in Hidradenitis Suppurativa First three patients dosed with vilobelimab in Phase II Cutaneous Squamous Cell Carcinoma trial Dr. Korinna Pilz promoted to Chief Clinical Development Officer Cash , cash equivalents and financial assets of approximately € 127.5 million as of June 30 , 2021 Jena , Germany , August 5 , 2021 InflaRx ( Nasdaq : IFRX ) , a clinical - stage biopharmaceutical company developing anti - inflammatory therapeutics by targeting the complement system , announced today financial and operating results for the three and six months ended June 30 , 2021 . " I am very pleased to announce the promotion of Dr. Korinna Pilz to Chief Clinical Development Officer . Korinna has an impressive background with more than 20 years of drug development experience in biotech and large pharma . Korinna has been instrumental in leading the development of our pipeline programs and building the internal clinical team over the past few years . Our team has been impressed by her professional excellence and we are wishing Korinna a great start in her new role . " said Prof. Niels C. Riedemann , Chief Executive Officer and Founder of InflaRx . " Our team has continued to work hard to advance the clinical development of vilobelimab in several indications , including the initiation of our first clinical trial for treating cancer patients . We are pleased that the independent data monitoring committee has recommended that the COVID - 19 trial shall continue as planned . Earlier clinical results with vilobelimab in this challenging disease showed promise and suggested that C5a inhibition might be beneficial in critically ill COVID - 19 patients . We look forward to the results of the Phase III trial , which is on track to read out by the end of this year . We also expect data readouts from our clinical trials in ANCA - associated Vasculitis and Pyoderma Gangraenosum by year end . With upcoming data from these trials as well as plans to meet